UK regulators no longer exempt from paying successful parties' costs
26-05-2022
FDA, FTC send message to biologics makers at competition workshop
10-03-2020
Judge refuses to block pay-for-delay law pending appeal
13-01-2020
Mark Van Scyoc / Shutterstock.com
US competition regulators will increase scrutiny of biologic and biosimilar-related patent settlements, as they look to crack down on antitrust violations.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Antitrust, biosimilars, US Federal Trade Commission, FTC, Patient Right to Know Drug Prices Act, US Court of Appeals for the Ninth Circuit, Food and Drug
